Cited by 84Nanoparticle-Based Drug DeliveryGlioma Diagnosis and TreatmentNanoplatforms for cancer theranostics

Application of nanoparticles on diagnosis and therapy in gliomas.

Open access
Hernández-Pedro, Norma Y., Rangel-López, Edgar, Magaña-Maldonado, Roxana, de la Cruz, Verónica Pérez, Santamaría del Angel, Abel, Pineda, Benjamín, Sotelo, Julio·2013·BioMed Research International

Abstract

Glioblastoma multiforme (GBM) is one of the most deadly diseases that affect humans, and it is characterized by high resistance to chemotherapy and radiotherapy. Its median survival is only fourteen months, and this dramatic prognosis has stilled without changes during the last two decades; consequently GBM remains as an unsolved clinical problem. Therefore, alternative diagnostic and therapeutic approaches are needed for gliomas. Nanoparticles represent an innovative tool in research and therapies in GBM due to their capacity of self-assembly, small size, increased stability, biocompatibility, tumor-specific targeting using antibodies or ligands, encapsulation and delivery of antineoplastic drugs, and increasing the contact surface between cells and nanomaterials. The active targeting of nanoparticles through conjugation with cell surface markers could enhance the efficacy of nanoparticles for delivering several agents into the tumoral area while significantly reducing toxicity in living systems. Nanoparticles can exploit some biological pathways to achieve specific delivery to cellular and intracellular targets, including transport across the blood-brain barrier, which many anticancer drugs cannot bypass. This review addresses the advancements of nanoparticles in drug delivery, imaging, diagnosis, and therapy in gliomas. The mechanisms of action, potential effects, and therapeutic results of these systems and their future applications in GBM are discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2013/351031

Cites

166 of 166 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ultra small gadolinium oxide crystals less than 5 nm in diameter have been successfully used to label glioma cells GL-261 in vivo.

    “Ultra small (less than 5 nm in diameter) gadolinium oxide crystals have been successfully used to label glioma cells GL-261 in vivo”

    From Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs (2020) · cites this paper as Hernández-Pedro et al., 2013

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hernández-Pedro, N. Y., Rangel-López, E., Magaña-Maldonado, R., de la Cruz, V. P., Santamaría del Angel, A., Pineda, B., & Sotelo, J.
Affiliations
  • Neuroimmunology and Neuro-Oncology Unit, National Institute of Neurology and Neurosurgery, 14269 Mexico City, DF, Mexico
  • Excitatory Amino Acids Laboratory, National Institute of Neurology and Neurosurgery, 3877 Mexico City, DF, Mexico
  • Instituto Nacional de Neurología y Neurocirugía (MX)
Corresponding author
Pineda, Benjamín
Venue
BioMed Research International
Publisher
Wiley
Published
2013
Volume
2013
Pages
1-20
ISSN
  • 1110-7243 (ISSN-L)
  • 2314-6133
  • 2314-6141
OpenAlex
W2056024740
Cited by
84
References
166
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 7 · 2022: 5 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 9 · 2015: 13 · 2014: 7 · 2013: 5
FWCI
0.77
Type
journal article
Language
en
Open access
Locations
  • BioMed Research International (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
glioblastoma, glioma, nanoparticles, drug delivery, targeted drug delivery, blood-brain barrier, tumor imaging, glioma diagnosis, glioma treatment, tumor-specific targeting, chemoresistance, radiotherapy resistance
MeSH terms
Animals, Antibodies, Brain Neoplasms, Glioma, Humans, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review